The Optic Neuritis Treatment Trial (ONTT) was a landmark study in the field of neuro-ophthalmology. This study provided a large-scale systematic view into the course and clinical characteristics of acute demyelinating optic neuritis (ON). ON may be the first clinical demyelinating event in up to 20% of patients with multiple sclerosis (MS) and the overall cumulative probability of developing clinically-definite MS, defined as a second clinical event, was 50% by 15 years after the onset of acute ON. Presence of magnetic resonance imaging (MRI)-detected brain lesions and oligoclonal bands were found to be associated with an increased risk of developing clinically definite MS (CDMS), defined by a second clinical demyelinating event.
Relation is Part of
NANOS Annual Meeting 2017: Hot Topics in OCT
Steven Galetta, MD
Spencer S. Eccles Health Sciences Library, University of Utah
2017 North American Neuro-Ophthalmology Society Annual Meeting